Xlife Sciences AG has confirmed its intention to secure a listing in the new Sparks equity segment of the SIX Swiss Exchange. “The new Sparks segment of the Swiss stock exchange is attractive for Xlife Sciences as an emerging growth company”, explains Dr. Bernhard Scholz, Chairman of the Board at Xlife Sciences, in a company press release. The Sparks segment was only launched in October 2021 with the aim of reducing the entry barriers for small and medium-sized enterprises (SMEs) looking to go public.
Xlife Sciences is planning to finalize its listing on this SIX Swiss Exchange subsegment in the first quarter of 2022. The company focuses on further development and commercialization activities related to promising life sciences research projects from universities and other research institutions. In so doing, there is a specific focus on preclinical projects.
Despite being headquartered in Zurich, Xlife Sciences is currently admitted to trading on the Munich Stock Exchange in Germany. According to information in the press release, the company has a market capitalization of 233 million euros as at year-end 2021. The planned switch to the SIX Swiss Exchange remains subject to financial market developments.
As Oliver R. Baumann, CEO of Xlife Sciences, explains further in the press release, the objective of the company’s planned listing in Switzerland and associated move to a regulated market, is to become “more accessible to institutional investors, increase the liquidity of the stock and further enhance the transparency of Xlife Sciences”.
Why Greater Zurich Area
Innovation thrives here
As a global leader in innovation and talent attraction, combined with Switzerland’s business friendly, stable and reliable environment, Greater Zurich offers international companies real added value for strategic expansion.
Where life science meets innovation
Do you want to be close to major players, innovative start-ups and leading research institutes in the life sciences space? The Greater Zurich Area has evolved into a dynamically expanding life sciences hotspot, thanks to the region’s academic excellence, business-friendly regulations, IP protection, large international talent pool and R&D collaborations between universities and start-ups, as well as large multinational corporations.